TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29699493
Drug: Under-treatment in
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under-treatment in ICU patients with risk factors for PA infection (74.2% under-treated)
Study: 29700101
Drug: Decision aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision aid (DA) in combination with a brief Q&A session with a genetic counsellor
Study: 29700172
Drug: Post-transplant infusion
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplant infusion of cyclophosphamide
Study: 29700872
Drug: Omalizumab-supplemented Oral
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab-supplemented Oral Immunotherapy (OIT)
Study: 29701107
Drug: Adjunctive naturopathic
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive naturopathic oncology (NO) specialty care
Study: 29703712
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied growth factors combined with protease inhibitor wound dressings
Study: 29703851
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups continue weekly self-administered subcutaneous MTX treatment (15-25 mg/week)
Study: 29705265
Drug: GS-0976 20
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-0976 20 mg orally once daily for 12 weeks
Study: 29705733
Drug: Topical immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical immunosuppression for GVHD
Study: 29706508
Drug: Air kerma
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air kerma radiation dose
Study: 29707537
Drug: Inertial Measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inertial Measurement Unit sensors during daily life
Study: 29707537
Drug: Daily-life recorded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily-life recorded kinematics
Study: 29707537
Drug: Daily-life activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily-life activities
Study: 29709062
Drug: Chemo-immunotherapy followed
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy followed by radio-immunotherapy and 2 years of rituximab maintenance
Study: 29709062
Drug: Radio-immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio-immunotherapy
Study: 29709062
Drug: Post radio-immunotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post radio-immunotherapy
Study: 29709062
Drug: Post treatment
Normalized name: HYDROCORTISONE 1 mg in 1 g TOPICAL CREAM [Post Treatment Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post treatment
Study: 29709335
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to insulin therapy
Study: 29710075
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg twice daily
Study: 29712654
Drug: Single-Dose Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Dose Oral LCB01-0371, a novel oxazolidinone
Study: 29713493
Drug: EcN suspension
Normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcN suspension orally for 3 weeks
Study: 29713493
Drug: EcN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcN treatment
Study: 29713524
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of Ranibizumab (IVR)
Study: 29713524
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of Bevacizumab (IVB)
Study: 29715056
Drug: Venetoclax 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 400 mg per day after an initial dose ramp up
Study: 29715056
Drug: Venetoclax for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax for patients who received prior kinase inhibitors
Study: 29716640
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg loading dose followed by 5 mg/kg/h maintenance infusion)
Study: 31201186
Drug: Auditory Brainstem
Normalized name: Sus scrofa brainstem preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory Brainstem Implant (ABI)
Study: 29718390
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg rifampicin (reference arm)
Study: 29718390
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg rifampicin
Study: 29718390
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg rifampicin
Study: 29718390
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg rifampicin
Study: 29718390
Drug: 35 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/kg rifampicin
Study: 29718390
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg rifampicin
Study: 29718390
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg rifampicin (predicted)
Study: 29720163
Drug: Pre-referral rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-referral rectal artesunate treatment
Study: 29720224
Drug: Non-TC chemotherapy
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-TC chemotherapy regimens
Study: 29720277
Drug: Optimal PEEP
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal PEEP titration
Study: 29720487
Drug: First-line therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line therapy for PMBCL
Study: 29720734
Drug: G-CSF, cladribine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF, cladribine, high-dose cytarabine, and dose-escalated mitoxantrone (GCLAM)
Study: 29721378
Drug: Vemurafenib (BRAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib (BRAF inhibitor) and aldesleukin (interleukin-2)
Study: 29722789
Drug: Weighted prevalence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weighted prevalence of regorafenib toxicity profile and dose reduction
Study: 29722836
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake ≥250-299 μg/d in 7- to 10-y-old children
Study: 29722836
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake ≥300-399 μg/d in 11- to 14-y-old children
Study: 29722838
Drug: Maternal intake
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal intake of total vitamin D (≥13.6 µg/d)
Study: 29722851
Drug: Calcium-to-magnesium ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 2
Study: 29722851
Drug: Calcium-to-magnesium ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 3
Study: 29722851
Drug: Calcium-to-magnesium ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 3 (stratified by race)
Study: 29723161
Drug: Metreleptin treatment
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin treatment for 14 days (initiation cohort)
Study: 29723161
Drug: Metreleptin treatment
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin treatment for 6 months on an ad libitum diet (initiation cohort)
Study: 29723397
Drug: Dasatinib 50 mg
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib 50 mg daily
Study: 29723689
Drug: Drugs not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs not toxic to MH cells
Study: 29724397
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) twice daily for 7 days with VHC
Study: 29724397
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) twice daily for 7 days without VHC
Study: 29726923
Drug: Brontictuzumab administered
Normalized name: Brontictuzumab
DrugBank: Brontictuzumab (DB12737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brontictuzumab administered intravenously at 1.5 mg/kg every 3 weeks (Q3W) during expansion phase.
Study: 29726923
Drug: Brontictuzumab administered
Normalized name: Brontictuzumab
DrugBank: Brontictuzumab (DB12737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brontictuzumab administered intravenously at various dose levels during dose escalation.
Study: 29727073
Drug: Ketamine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusions (0.5 mg/kg)
Study: 29728755
Drug: Remifentanil (2.68-3.11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (2.68-3.11 µg/kg) co-administered with propofol (3 mg/kg)
Study: 29730377
Drug: Dexamethasone delivery
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone delivery adjunctive to standard endovascular revascularization
Study: 29730615
Drug: High-dose medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medical exercise therapy (MET) - 70-90 minutes per session, 3 times a week for 12 weeks (total of 36 sessions)
Study: 29730615
Drug: Low-dose medical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose medical exercise therapy (MET) - 20-30 minutes per session, 3 times a week for 12 weeks (total of 36 sessions)
Study: 29731369
Drug: Tailored frequency-escalated
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored frequency-escalated primary prophylaxis with standard half-life recombinant factor VIII (SHL-rFVIII), starting at 50 IU/kg once weekly, escalating in frequency and dosage as needed.
Study: 29731779
Drug: NSC-mediated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSC-mediated therapy
Study: 29733524
Drug: Veliparib extended-release
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib extended-release (ER) 800 mg once daily or 600 mg twice daily
Study: 29733524
Drug: Veliparib extended-release
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib extended-release (ER) 200 mg (fasting)
Study: 29733524
Drug: Veliparib extended-release
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib extended-release (ER)
Study: 29733771
Drug: Birabresib 80
Normalized name: Birabresib
DrugBank: Birabresib (DB15189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birabresib 80 mg once daily (cohort A)
Study: 29733771
Drug: Birabresib 100
Normalized name: Birabresib
DrugBank: Birabresib (DB15189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birabresib 100 mg for 7 consecutive days (cohort B)
Study: 29733771
Drug: Birabresib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birabresib (80 mg once daily)
Study: 29733771
Drug: Birabresib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birabresib (80 mg once daily) in patients with NMC
Study: 29734948
Drug: Aerosolized inhaled
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 800 μg twice daily for 1 week
Study: 29734948
Drug: Aerosolized inhaled
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 200 μg twice daily for 1 week
Study: 29734948
Drug: Aerosolized inhaled
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 400 μg twice daily for 1 week
Study: 29734948
Drug: Aerosolized inhaled
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 600 μg twice daily for 1 week
Study: 29734953
Drug: Amisulpride (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (dopamine D2/3 receptor antagonist) treatment for 6 weeks
Study: 29734990
Drug: PAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP therapy for 6 weeks
Study: 29734990
Drug: Exosomes isolated
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosomes isolated before PAP therapy
Study: 29734990
Drug: Exosomes isolated
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosomes isolated after PAP therapy
Study: 29735299
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor (TKI) therapy discontinuation
Study: 29735299
Drug: Imatinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib as first-line treatment
Study: 29736468
Drug: Standard method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard method (empirical fluid administration)
Study: 29736473
Drug: 4 cups
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cups of instant regular coffee daily
Study: 29736473
Drug: 4 cups
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cups of a coffee-like placebo beverage daily
Study: 29737243
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of paracetamol
Study: 30583256
Drug: Desvenlafaxine (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (50-100 mg/day)
Study: 29739356
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of consolidation chemotherapy before TME, followed by 5 cycles of adjuvant chemotherapy (experimental arm)
Study: 29739356
Drug: 8 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 cycles of adjuvant chemotherapy (control arm)
Study: 29739389
Drug: Higher-protein group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-protein group (median protein intake 4.3 g/kg/d)
Study: 29739389
Drug: Lower-protein group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-protein group (median protein intake 3.7 g/kg/d)
Study: 29739393
Drug: Nursing home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing home treatment for dehydration or bacterial infections
Study: 29739393
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment for dehydration or bacterial infections
Study: 29739754
Drug: Dexpramipexole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpramipexole (150 mg orally twice daily)
Study: 29740788
Drug: Provider education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider education on guidelines for the appropriate treatment of ARIs
Study: 29741298
Drug: Bevacizumab pre-treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab pre-treatment in mice
Study: 29741697
Drug: l-lysine (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-lysine (10, 13, 16, and 18 mg · kg-1 · d-1)
Study: 29741697
Drug: l-tryptophan (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-tryptophan (0.5, 1, 1.5, and 2 mg · kg-1 · d-1)
Study: 29742009
Drug: Neoadjuvant dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant dose-dense gemcitabine and cisplatin (ddGC)
Study: 29742471
Drug: Initial antibiotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotic therapy (IAT) received ≤ 48 h post-initiation, mean duration 8.8 days, 62.5% received monotherapy.
Study: 29743148
Drug: Secondary cytoreductive
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary cytoreductive surgery followed by platinum-based chemotherapy
Study: 29745476
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy with prasugrel/ticagrelor at discharge
Study: 29746639
Drug: BCAA diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA diet (1.03 g · kg-1 · d-1)
Study: 29746639
Drug: EAA diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAA diet (1.23 g · kg-1 · d-1)
Study: 29746639
Drug: SUF diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUF diet (1.75 g · kg-1 · d-1)
Study: 29746639
Drug: NEAA diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEAA diet (1.75 g · kg-1 · d-1)
Study: 29746639
Drug: BASE diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: BASE diet (0.8 g · kg-1 · d-1)
Study: 29747074
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day of zinc from day +5 to day +100 after transplant
Study: 29747670
Drug: Jiedu Tongluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiedu Tongluo granules (JDTLG) with conventional treatment
Study: 29747670
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with conventional treatment
Study: 29747700
Drug: Myo-inositol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (2 g, twice per day) for three months followed by myo-inositol plus alpha-lactalbumin (50 mg, twice per day) for three months
Study: 29747700
Drug: Myo-inositol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (2 g, twice per day) for three months
Study: 29747700
Drug: Myo-inositol plus
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol plus alpha-lactalbumin (50 mg, twice per day)
Study: 29747838
Drug: High-Dose Ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-Dose Ferric Carboxymaltose
Study: 29748160
Drug: Activity tracking
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity tracking with weekly review of self-reports and activity information.
Study: 29748160
Drug: Activity tracking
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity tracking and self-reporting with weekly review.
Study: 29748344
Drug: Data collection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection and abstraction of patient characteristics, diagnostic testing, treatments, and in-hospital outcomes.
Study: 29748435
Drug: End-of-treatment PET
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-treatment PET (negative Deauville 1-3)
Study: 29748435
Drug: End-of-treatment PET
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-treatment PET (positive Deauville 4-5)
Study: 29748444
Drug: Bendamustine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine (90 mg/m²) plus Rituximab
Study: 29750067
Drug: Non-vitamin-K-antagonist oral
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin-K-antagonist oral anticoagulant (NOAC) treatment
Study: 29750067
Drug: Vitamin-K-antagonist (VKA)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-K-antagonist (VKA) treatment
Study: 29750396
Drug: Cabazitaxel at
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel at a starting dose of 20 mg/m², escalated to a maximum tolerated dose (MTD) of 30 mg/m².
Study: 29750396
Drug: Cabazitaxel at
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel at a dose of 35 mg/m².
Study: 29750699
Drug: Closed-loop-assisted goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop-assisted goal-directed fluid therapy (GDFT) with a baseline crystalloid infusion of 3 ml/kg/h and additional 100 ml fluid boluses of crystalloid or colloid.
Study: 29750699
Drug: Closed-loop-assisted goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop-assisted goal-directed fluid therapy (GDFT)
Study: 29750747
Drug: Clofarabine at
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine at a dose of 50 mg/m/d for 5 days
Study: 29750766
Drug: Maternal viral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal viral load >1,000,000 copies/mL at delivery
Study: 29751792
Drug: gemcitabine-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine-based chemotherapy
Study: 29752199
Drug: R-GemOx regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-GemOx regimen (rituximab 375 mg/m2, gemcitabine, and oxaliplatin) administered intravenously as first-line treatment.
Study: 29752199
Drug: R-GemOx regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-GemOx regimen (rituximab 375 mg/m2, gemcitabine, and oxaliplatin) administered intravenously.
Study: 29752388
Drug: PCI plus
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI plus optimal medical therapy (OMT)
Study: 29753517
Drug: Liberal fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluids approach (50 to 75 mL/kg during the first 6 hours)
Study: 29753517
Drug: Restrictive fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluids approach (≤30 mL/kg)